{"commentary":{"count":30,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"podcast":9,"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05939414\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PSMA-DC","nct_id":"NCT05939414","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=psma-dc-nct05939414. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PSMA-DC","arms":[{"description":"All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.","label":"Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)","type":"EXPERIMENTAL"},{"description":"All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.","label":"Control arm: observation (watchful waiting)","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2031-10-03","type":"ESTIMATED"},"conditions":["Oligometastatic Prostate Cancer (OMPC)"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AAA617","type":"DRUG"},{"name":"piflufolastat (18F)","type":"DRUG"},{"name":"gallium (68Ga) gozetotide (25μg)","type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Novartis Pharmaceuticals","official_title":"An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)","timeFrame":"From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months"}],"references":[],"start_date":{"date":"2024-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","url":"https://clinicaltrials.gov/study/NCT05939414"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/psma-dc-nct05939414"}